Hans-Peter Hartung Selected Research

Macular Edema

10/2017	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
9/2015	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
2/2010	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Peter Hartung Research Topics

Disease

223	Multiple Sclerosis 05/2024 - 12/2002
43	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 05/2024 - 04/2002
43	Relapsing-Remitting Multiple Sclerosis 01/2023 - 05/2003
28	Demyelinating Diseases (Demyelinating Disease) 01/2024 - 12/2002
27	Polyneuropathies (Polyneuropathy) 01/2023 - 06/2005
26	Infections 10/2023 - 03/2003
22	Neuromyelitis Optica (Devic's Disease) 06/2024 - 02/2012
22	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 06/2004
19	Chronic Progressive Multiple Sclerosis 10/2022 - 12/2002
18	Progressive Multifocal Leukoencephalopathy 01/2023 - 02/2007
15	Inflammation (Inflammations) 10/2022 - 04/2002
14	Guillain-Barre Syndrome 01/2024 - 04/2002
12	Stroke (Strokes) 09/2020 - 07/2004
10	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 03/2006
10	Disease Progression 07/2022 - 06/2004
9	COVID-19 06/2024 - 06/2020
9	Ischemic Stroke 09/2020 - 07/2004
9	Neoplasms (Cancer) 07/2020 - 03/2006
8	Optic Neuritis (Retrobulbar Neuritis) 01/2022 - 01/2012
7	Myasthenia Gravis 01/2024 - 07/2006
7	Nervous System Diseases (Neurological Disorders) 01/2021 - 07/2006
6	Atrophy 03/2022 - 07/2013
6	Headache (Headaches) 01/2022 - 09/2010
5	Experimental Autoimmune Neuritis 01/2018 - 02/2004
4	Neuroinflammatory Diseases 01/2023 - 01/2016
4	Pain (Aches) 01/2022 - 10/2004
4	Autoimmune Diseases of the Nervous System 11/2021 - 03/2010
4	Rheumatoid Arthritis 10/2020 - 01/2009
4	Opportunistic Infections (Opportunistic Infection) 04/2020 - 02/2007
4	Infarction (Infarctions) 01/2020 - 06/2012
4	Ganglion Cysts (Ganglion) 11/2019 - 01/2012
3	Central Nervous System Diseases (CNS Diseases) 01/2023 - 07/2006
3	Fever (Fevers) 01/2022 - 09/2010
3	Encephalitis (Encephalitis, Rasmussen) 11/2021 - 10/2007
3	Myositis (Idiopathic Inflammatory Myopathies) 11/2021 - 09/2006
3	Lymphopenia (Lymphocytopenia) 04/2020 - 12/2014
3	Atrioventricular Block 11/2019 - 02/2010
3	Human Influenza (Influenza) 01/2019 - 09/2010
3	Macular Edema 10/2017 - 02/2010

Drug/Important Bio-Agent (IBA)

34	Natalizumab (Tysabri)FDA Link 01/2023 - 04/2005
27	Intravenous Immunoglobulins (IVIG)FDA Link 05/2024 - 02/2008
27	Interferon-betaIBA 01/2019 - 06/2003
22	Fingolimod Hydrochloride (FTY720)FDA Link 05/2022 - 02/2010
20	Monoclonal AntibodiesIBA 10/2023 - 04/2005
19	AntibodiesIBA 03/2024 - 12/2002
18	Immunoglobulin G (IgG)IBA 06/2024 - 07/2005
18	InterferonsIBA 01/2023 - 05/2003
17	Immunoglobulins (Immunoglobulin)IBA 05/2024 - 11/2007
17	Retinaldehyde (Retinal)IBA 01/2022 - 01/2012
17	Interferon beta-1a FDA Link 11/2019 - 09/2005
16	Proteins (Proteins, Gene)FDA Link 03/2024 - 03/2003
15	Alemtuzumab (Campath)FDA Link 01/2023 - 01/2009
13	ocrelizumabIBA 04/2024 - 10/2016
13	Interferon beta-1b (Betaseron)FDA Link 01/2020 - 08/2007
12	CytokinesIBA 01/2023 - 12/2002
12	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2023 - 12/2002
11	VaccinesIBA 01/2024 - 09/2010
11	Glatiramer Acetate (Copaxone)FDA Link 01/2023 - 06/2003
11	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2004
10	HizentraIBA 01/2022 - 01/2016
9	inebilizumabIBA 06/2024 - 10/2019
9	Myelin-Oligodendrocyte GlycoproteinIBA 01/2023 - 12/2006
9	Cladribine FDA LinkGeneric 11/2021 - 02/2010
8	AutoantibodiesIBA 01/2023 - 12/2006
8	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023 - 06/2004
8	Sphingosine-1-Phosphate ReceptorsIBA 10/2022 - 10/2012
8	Rituximab (Mabthera)FDA Link 01/2022 - 10/2005
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 05/2004
7	ozanimodIBA 12/2023 - 01/2019
7	GadoliniumIBA 04/2021 - 04/2014
7	AntigensIBA 01/2021 - 02/2004
6	Neutralizing AntibodiesIBA 06/2012 - 06/2004
5	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2018
5	tocilizumab (atlizumab)FDA Link 01/2022 - 03/2013
5	4-Aminopyridine (4 Aminopyridine)FDA Link 01/2021 - 11/2012
5	CaprylatesIBA 02/2012 - 02/2008
4	ChemokinesIBA 03/2024 - 04/2002
4	Aquaporin 4IBA 10/2023 - 03/2013
4	siponimodIBA 10/2022 - 08/2013
4	temelimabIBA 03/2022 - 12/2012
4	TabletsIBA 04/2021 - 01/2013
4	Aquaporins (Water Channels)IBA 01/2016 - 02/2012
3	Complement System Proteins (Complement)IBA 03/2024 - 11/2016
3	COVID-19 VaccinesIBA 01/2024 - 01/2022
3	teriflunomideIBA 01/2023 - 01/2009
3	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2006
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2022 - 03/2013
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2021 - 10/2009
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2020 - 11/2012
3	Vitamin D FDA LinkGeneric 01/2020 - 03/2014
3	Oligoclonal BandsIBA 05/2019 - 12/2014
3	Peptides (Polypeptides)IBA 01/2019 - 11/2005
3	SteroidsIBA 10/2018 - 06/2011
3	Simvastatin (Zocor)FDA LinkGeneric 01/2016 - 01/2005
3	IntegrinsIBA 01/2015 - 04/2005

Therapy/Procedure

117	Therapeutics 06/2024 - 12/2002
16	Immunotherapy 01/2022 - 07/2005
9	Immunomodulation 01/2022 - 03/2003
6	Plasma Exchange 11/2018 - 07/2006
3	Transplantation 09/2014 - 09/2006